Advanced Search

 

Study ID Status Title Patient Level Data
EPI40105 Completed A post-marketing surveillance study of subject-reported adverse events rates for Malarone (atovaquone and proguanil), mefloquine and chloroquine/proguanil, when used for prophylaxis for travel up to 28 days maximum
FAP10001 Completed Dose proportionality of fluticasone propionate from HFA inhalers and effect of propellant on FP pharmacokinetics Study Listed on ClinicalStudyDataRequest.com
FAP10006 Completed A Randomized, Open-Label, 2-Way Crossover, Repeat-Dose Study in Pediatric Subjects with Asthma, Age 4-11 Years, to Compare Systemic Exposure of Fluticasone Propionate 2x44mcg Following Administration by Metered-Dose Inhalers Containing Hydrofluoroalkane or Chlorofluorocarbon Propellants Study Listed on ClinicalStudyDataRequest.com
FAP19052 Completed Pharmacodynamics of the 88mcg BID dose of the Hydrofluoroalkane propellant formulation of inhaled Fluticasone Propionate following Administration via the Metered-dose Inhaler in Pediatric Subjects 4 to 11 years of age with Asthma Study Listed on ClinicalStudyDataRequest.com
FAP19058 Completed Systemic exposure of the fluticasone propionate from the hydrofluoroalkane propellant formulation via the metered-dose inhaler with and without a spacer in pediatric subjects 4 to 11 years of age with asthma. Study Listed on ClinicalStudyDataRequest.com
FAP30007 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy Study Listed on ClinicalStudyDataRequest.com
FAP30008 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy Study Listed on ClinicalStudyDataRequest.com
FAP30010 Completed A Randomized, Double-Blind, Paralled-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg Twice Daily versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 years of age with Asthma Study Listed on ClinicalStudyDataRequest.com
FAS10002 Completed A multiple-dose, open-label, 2-way crossover study in pediatric subjects with asthma aged 1 to < 4 years to compare the systemic exposure of fluticasone propionate 88mcg administered via the hydrofluoroalkane metered-dose inhaler using the valved holding chambers, Aerochamber Plus™ and Babyhaler™, with face-masks Study Listed on ClinicalStudyDataRequest.com
FAS106533 Completed PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma Study Listed on ClinicalStudyDataRequest.com
FAS30007 Completed A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms. Study Listed on ClinicalStudyDataRequest.com
FAS30009 Completed A multicentre, randomised, parallel-group open label study to assess the long term safety of fluticasone propionate 100mcg bd via the MDI and babyhaler spacer device, compared with sodium cromoglycate 5mg QDS in children aged 12-47months with documented evidence of recurrent/persistent asthma-like symptoms. Study Listed on ClinicalStudyDataRequest.com
FAS30030 Completed A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Safety and Efficacy Study of Fluticasone Propionate 88mcg BID Versus Placebo BID delivered via HFA MDI and a valved holding chamber with facemask in Pediatric Subjects with Asthma age 12 months to 47 months. Study Listed on ClinicalStudyDataRequest.com
FAS40008 Completed An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life? Study Listed on ClinicalStudyDataRequest.com
FAS40008_1 Completed An interventional three year study for asthma control - In what way and in what kind of population is it possible toget asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life?
FAS40012 Completed Early Intervention with Inhaled Corticosteroids in Wheezing Pre-school Children: A Single-Centre, Double-Blind, Randomised 5 Years Parallel-Group Study Comparing Adjusted Dosing of Inhaled Fluticasone Propionate With Inhaled Placebo Both Administered by Metered Dose Inhaler via a Babyhaler. Study Listed on ClinicalStudyDataRequest.com
FFA10001 Completed A randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GW685698X in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
FFA10002 Completed A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability and systemic pharmacokinetics and pharmacodynamics of repeat doses (500, 1000 and 2000mg) of GW685698X administered once daily for fourteen da Study Listed on ClinicalStudyDataRequest.com
FFA10003 Completed A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of GW685698X and FP (1000mg) administered via Diskhaler® in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
FFA10007 Completed A randomised, double-blind, placebo-controlled, 5-way cross incomplete block design study to investigate the relative potency of single inhaled doses of GW685698X (3µm material) and fluticasone propionate (FP) on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FFA10008 Completed A randomised, single dose, open label, 3-way cross-over study to assess the systemic pharmacokinetics of GW685698X (1000mg) administered via Diskhaler with or without charcoal and an intravenous dose (250mg) in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
FFA10009 Completed A randomised, double-blind, placebo-controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability and PK of once daily inhaled GW685698 with the excipient COA administered via DISKUS in healthy subjects Study Listed on ClinicalStudyDataRequest.com
FFA10013 Completed A study to investigate the pharmacokinetics of a single inhaled dose (400mcg) of GW685698X and its effect on serum cortisol in patients with impaired liver function and matched control subjects. Study Listed on ClinicalStudyDataRequest.com
FFA10022 Completed A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients Study Listed on ClinicalStudyDataRequest.com
FFA10026 Completed A randomised, double-blind, placebo-controlled, six-way cross design study to investigate the effect of single inhaled doses of NCE and fluticasone propionate on airway responsiveness to adenosine 5’-monophosphate challenge in mild asthmatic patients. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.